On 20 May, the company TauRx Therapeutics Ltd, based in Aberdeen (Scotland), published analysis of its drug hydromethylthionine (TRx0237) in the journal of Alzheimer’s Disease. Hydromethylthionine acts by blocking abnormal accumulation of Tau protein in the brain.
TauRx conducted a randomised, controlled, double-blind and parallel-group Phase III study in 220 people with behavioural variant Fronto-Temporal Dementia (bvDTD) between 2013 and 2016. The 52 week Phase III trial study recruited participants younger than 80 years of age with a diagnosis of bvFTD at 70 sites in Canada, United States, Australia, Asia and Europe. Research participants received the drug, taken as a tablet, at doses of 8 or 200 mg/day. Findings showed that hydromethylthionine had statistically significant effects on clinical decline and brain atrophy. There were no significant differences on any of the outcomes at 52 weeks between the participants receiving the drug at 8 mg/day and those receiving 200 mg/day. The company is planning to conduct a confirmatory placebo-controlled trial.
TauRx is also developing this drug for the treatment of Alzheimer’s disease (AD) in a Phase III trial. The LUCIDITY trial is a randomised, double-blind and placebo-controlled study evaluating the safety and efficacy of hydromethylthionine in people with mild to moderate AD in US, Canada and Europe.
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad191173
